Klippstein T H, Mitrou P S, Kochendörfer K J, Bergmann L
Cancer Chemother Pharmacol. 1984;13(2):78-81. doi: 10.1007/BF00257118.
Eighteen previously untreated patients with advanced unresectable or metastatic soft-tissue sarcomas (STS) and two patients with locally invasive thymoma were treated with a combination of adriamycin (ADM) 80 mg/m2 on day 1 and cis-platinum (DDP) 120 mg/m2 on day 1. The regimen was repeated at 4-weeks intervals. In STS the overall remission rate was 44%, with 21% complete remissions. The overall survival was 15 months (3-35+), responders surviving a median of 20 months (3-35+) and nonresponders, a median of 9 months (3-20+). Tumor responses lasted a median of 8 months (3-35+). Two patients with liposarcoma have now survived disease-free for at least 2 years and are potentially cured. The two patients with thymoma experienced complete remission lasting 4+ and 20+ months. Substantial hematologic toxicity was prominent, due to the high-doses used in this combination regimen.
18例先前未经治疗的晚期不可切除或转移性软组织肉瘤（STS）患者和2例局部侵袭性胸腺瘤患者接受了如下联合治疗：阿霉素（ADM）80mg/m²于第1天给药，顺铂（DDP）120mg/m²于第1天给药。该方案每4周重复一次。在STS患者中，总缓解率为44%，完全缓解率为21%。总生存期为15个月（3 - 35 +），缓解者的中位生存期为20个月（3 - 35 +），未缓解者的中位生存期为9个月（3 - 20 +）。肿瘤反应持续的中位时间为8个月（3 - 35 +）。2例脂肪肉瘤患者现已无病生存至少2年，可能已治愈。2例胸腺瘤患者经历了持续4 +和20 +个月的完全缓解。由于该联合方案使用的剂量较高，严重的血液学毒性较为突出。
